Tomljenovic L, Shaw CA. Early career postdoctoral fellow in the Neural Dynamics Research Group at the University of British Columbia. Professor in the Department of Ophthalmology and Visual Sciences at the University of British Columbia and holds cross appointments with the Program in Experimental Medicine and the Graduate Program in Neuroscience. Abstract There are not many […]
Death after Quadrivalent Human Papillomavirus (HPV) Vaccine: Causal or Coincidental?
Lucija Tomljenovic1* and Christopher A Shaw1,2,3 1Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada 2Program in Experimental Medicine, University of British Columbia, Canada 3Program in Neuroscience, University of British Columbia, Canada Abstract: Background: The proper understanding of a true risk from vaccines is crucial for avoiding unnecessary adverse reactions (ADRs). However, to […]
Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?
Tomljenovic L, Shaw CA, Spinosa JP. Source Department of Ophthalmology and Visual Sciences, University of British Columbia, 828 W. 10th Ave, Vancouver, BC, V5Z 1L8, Canada. lucijat77@gmail.com. Abstract We carried out a systematic review of HPV vaccine pre- and post-licensure trials to assess the evidence of their effectiveness and safety. We find thatHPV vaccine clinical trials design, and data interpretation […]
Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness
Published in the Journal of the Royal Society of Medicine; June 2012 105:229 Authors: I Mattheij,1 AM Pollock,2 P Brhlikova3 Summary The Indian government suspended research in April 2010 on the feasibility and safety of human papillomavirus (HPV) vaccine in two Indian states (Andhra Pradesh and Gujarat) amid public concerns about its safety. This paper describes cervical cancer […]
Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard®
Philippe Halfon,1,2 Sophie Ravet,3 Hacène Khiri,1 Guillaume Penaranda,1,2,3 and Carole Lefoll2 1 Laboratoire Alphabio, Marseille, France 2 Hopital Ambroise Paré, Marseille, France 3 CDL Pharma, Marseille, France Corresponding author email: philippe.halfon@alphabio.fr This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Abstract We report the case of a 19-year-old woman who received a complete vaccine […]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 21
- Next Page »
